Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial (Q39436762)

12 September 2017

Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial (English)

1 reference

12 September 2017

phase II clinical trial

0 references

1 reference

1 reference

1 reference

Der-Yang Cho

1

1 reference

12 September 2017

Wen-Kuang Yang

2

1 reference

12 September 2017

Han-Chung Lee

3

1 reference

12 September 2017

Den-Mei Hsu

4

1 reference

12 September 2017

Hung-Lin Lin

5

1 reference

12 September 2017

Shinn-Zong Lin

6

1 reference

12 September 2017

Chun-Chung Chen

7

1 reference

12 September 2017

Horng-Jyh Harn

8

1 reference

12 September 2017

Chun-Lin Liu

9

1 reference

12 September 2017

Wen-Yuan Lee

10

1 reference

12 September 2017

Li-Hui Ho

11

1 reference

12 September 2017

7 November 2011

1 reference

12 September 2017

1 reference

12 September 2017

77

1 reference

12 September 2017

5-6

1 reference

12 September 2017

736-744

1 reference

Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study

12 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Recent advances of dendritic cells (DCs)-based immunotherapy for malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Invariant natural killer T cells are preserved in patients with glioma and exhibit antitumor lytic activity following dendritic cell-mediated expansion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Immunotherapeutic strategies for malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Immunotherapy of cancer with dendritic-cell-based vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Glioblastoma multiforme: pathology, natural history and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Cancer surveillance series [corrected]: brain and other central nervous system cancers: recent trends in incidence and mortality.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

?-Irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Systematic comparison of dendritic cell-based immunotherapeutic strategies for malignant gliomas: in vitro induction of cytolytic and natural killer-like T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Dendritic cell-based immunotherapy of malignant gliomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Report from the International Union Against Cancer (UICC) Tumor Biology Committee: UICC workshop on the use of dendritic cells in cancer clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Treatment of patients with primary glioblastoma multiforme with standard postoperative radiotherapy and radiosurgical boost: prognostic factors and long-term outcome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Brain tumor survival: results from the National Cancer Data Base

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Dendritic cell vaccination in patients with malignant gliomas: current status and future directions.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

The generation of anti-tumoral cells using dentritic cells from the peripheral bloood of patients with malignant brain tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2011.08.020

10.1016/J.WNEU.2011.08.020

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference